CORRECTION OF RESISTANT ARTERIAL HYPERTENSION IN PATIENTS WITH CHRONICKIDNEYDISEASE STAGE I–III
Aim. The aim was to investigate the use of the I1–imidazoline receptor agonist moxonidine as an ‘add–on’ agent and determine its effect on heart rate variability in patients with CKD st. I–III and resistant hypertension. Methods. We investigated the safety and efficacy of moxonidine (200–600 mg)...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Kidney Foundation of Ukraine
2014-08-01
|
| Series: | Український Журнал Нефрології та Діалізу |
| Subjects: | |
| Online Access: | https://ukrjnd.com.ua/index.php/journal/article/view/36 |